Thymectomy and glucocorticoids are the main treatments but they induce operative risks and side effects, respectively. The aim of this study was to propose new therapies more efficient for MG. We hypothesized that molecules dysregulated in MG thymus and normalized by glucocorticoids may play a key role in thymic pathogenesis. Using gene chip analysis, we identified 88 genes complying with these criteria, the most remarkable being the B cell chemoattractant (CXCL13). Its expression was increased in thymus and sera of glucocorticoid untreated patients and decreased in response to treatment in correlation with clinical improvement. Normal B cells were actively chemoattracted by thymic extracts from glucocorticoid untreated patients, an effect inhibited by anti-CXCL13 antibodies. In the thymus, CXCL13 was preferentially produced by epithelial cells and overproduced by epithelial cells from MG patients. Altogether, our results suggest that a high CXCL13 production by epithelial cells could be responsible for germinal centre formation in MG thymus. Furthermore, they show that this gene is a main target of corticotherapy. Thus, new therapies targeting CXCL13 could be of interest for MG and other autoimmune diseases characterized by ectopic germinal centre formation.
Introduction
Myasthenia Gravis (MG) is a neuromuscular disease with an autoimmune or a congenital etiology 1 . It is characterized by a defect in neuromuscular transmission, causing muscle weakness 2 . In 85% of cases, autoimmune MG is caused by autoantibodies directed against the nicotinic acetylcholine receptors (AChR) at the neuromuscular junction 3 . Thymic hyperplasia occurs in 60 % of MG patients with anti-AChR antibodies, is especially found in young women (< 40 years old) and consists in the formation of germinal centres (GCs) in the thymus 4 . Although GCs are normally found in secondary lymphoid organs 5, 6 , ectopic GCs are described in many autoimmune diseases such as chronic arthritis, Sjogren's syndrome and
Hashimoto thyroiditis [7] [8] [9] . In MG disease, there is a clear association between the presence of GCs and anti-AChR antibody production, since B cells purified from MG thymic hyperplasia are able to spontaneously produce antibodies to AChR 10 and thymectomy is an efficient therapy leading to a gradual decrease of anti-AChR antibody titer 11 . In addition thymic cells or fragments grafted in the SCID model produce anti-AChR antibodies accompanied with several signs of MG 12 . However, the mechanism underlying the abnormal migration of B cells towards the thymus is so far unknown.
Although progress has been made in developing therapies for MG, this disease is still incapacitating 13, 14 . Among the treatments used, anti-cholinesterasic agents have a rapid effect based on the inhibition of acetylcholine degradation 14 , but their action is only symptomatic.
When applied appropriately, glucocorticoids with their anti-inflammatory properties appear to be effective in most severe cases. However, their therapeutic use is limited by their severe side-effects, particularly during long-term treatment 15 . Thymectomy is often indicated when the thymus is hyperplastic and is effective in most cases 14 . However, it involves risks associated with the surgery 16 and the clinical status of the patients can remain unstable not
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Therefore, the existing treatments are far from being satisfactory in MG. Development of better therapies depends on a greater understanding of the mechanisms underlying thymic abnormalities, and namely the GC formation in the thymus.
Thus the aim of this study was to identify novel molecules involved in the pathogenic mechanisms of autoimmune MG that could serve as potential targets for a selective therapy.
Molecules dysregulated in MG patients and normalized by corticosteroids could serve such a function. Using DNA microarray technology, we identified a high proportion of genes associated with B cell functions that fulfill these criteria. We focused on CXCL13, since this molecule is highly attractive for B cells, and is important in GC formation and maintenance under physiological conditions [18] [19] [20] . Our results showed an elevated CXCL13 production by thymic epithelial cells (TEC) during MG, probably responsible for B cell attraction and by the way for GC formation in the thymus.
Materials and methods

Biological material
Thymic tissues and sera were taken from MG patients during thymectomy and from controls with healthy thymus during cardiac surgery at the Centre Chirurgical Marie-Lannelongue, Le were obtained after thymectomy during clinical follow-up. Sera obtained from ten sex-and age-matched adults were used as controls.
Cell isolation and culture conditions
Thymocytes were extracted mechanically by mincing freshly harvested thymuses in HBBS (Hank's Balanced Salts) (Gibco-invitrogen, Cergy-Pontoise, France). TEC were established as previously described 22 . To obtain thymic fibroblasts, thymic explants were cultured as described 22 , and after 7 days of culture, cells were submitted to a brief trypsin treatment to collect the fibroblasts that detach faster than TEC. The isolated cells were then cultured for an additional 7 days. Myoid immortalized thymic cells (MITC) is a cell line established as previously described 23 . Peripheral blood mononuclear cells (PBMC) were isolated from fresh blood via Ficoll gradient (CMSMSL01-01, Eurobio, les-Ulis, France).
Different dexamethasone concentrations (0, 0.1, 0.2, 0.3, 0.4 mg/ml) were added for 24 and 48 hours to subcultured TEC 22 . Supernatants were collected and stored at -80°C for ELISA.
For flow cytometry analysis, TEC were treated for 4 hours with 10 µg/ml of brefeldin-A 
Statistical analysis
To identify differentially expressed genes in thymuses from untreated MG patients compared to adult controls, the ratios were analyzed with the two-class unpaired algorithm of the Significance Analysis of Microarrays software (SAM-version 1.21, Stanford University, USA) 24 . The dysregulated genes were selected based on a False Discovery Rate (FDR) < 5%
and an average Fold-Change (FC) > 1.8. Among these genes, very few exhibited a low fluorescence intensity defined by a threshold corresponding to 1.5 background.
To determine the general effects of corticotherapy during MG, 8 K-Medians clustering analysis (Euclidean Squared, Log) using Acuity software, version 3.1 (Axon Instruments) was applied on the median of ratios of the three comparisons (adult controls/reference, untreated MG patients/reference and treated MG patients/reference) for the genes identified by SAM.
To assign a statistical value to these genes, we compared, using a nonparametric MannWhitney's test (Test U), the relative gene expression ratio between untreated and treated MG patients. A gene was considered significantly dysregulated if the P-value was < 0.05. sense 5'tggaaccacggtcacttaca 3', anti-sense 5'ctccaggtgcctctttcttg 3'. Hybridization was performed at 62°C for 12 seconds for all the primer pairs used. Successful preparation of cDNA was independently checked by amplification of the 28S gene.
Expression profiling by real-time PCR
Thymic protein extraction
For ELISA measurements, total thymic proteins were extracted in solution containing 5% Tris HCl 20mM, pH 7.4, 0.1% Triton X100 and one tablet of protease inhibitor cocktail (complete-mini Roche-Diagnostics, Meylan, France) using the fast prep apparatus.
CXCL13 ELISA Capture (MAB801) and detection (BAF801) CXCL13 antibodies (R&D, Lille, France) were used at 2.5 µg/ml and 0.25 µg/ml respectively. Recombinant human CXCL13 (801-CX-025, R&D) was used as standard. Thymic proteins were normalized to 1500 µg/ml and sera were diluted at 1/50 in 0.1% BSA in PBS. Tetramethylbenzedine was used for color development and plates were read at 450 nm on a MRX reader (DYNEX-technologies commercialized by ThermoLabsystems, Cergy-pontoise, France). Several samples were tested several times in the same assay, or in different assays, and the variance was less than 20%.
Chemotaxis assay
To eliminate monocytes and adherent cells, PBMC were cultured 24h prior to the assay in RPMI containing 0.5% fetal calf serum (FCS). To perform the assay, 24-well plates were used. PBL were seeded in RPMI containing 0.5% fetal calf serum at 2x10 6 cells/insert (PI8P01250, Millipore, Saint-Quentin, France). Thymic extracts were prepared by
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Flow cytometry analysis
Flow cytometry was carried out on permeabilized TEC as previously described 26 using anti-CXCL13 MAB801 antibody (R&D) revealed by goat anti-mouse coupled to phycoerythrin (R0480 Dakocytomation).
Laser Microdissection
Cryostat sections (7 µm) of frozen human thymic tissues were affixed to glass foil slides for membrane based laser microdissection (Leica, Rueil-Malmaison, France), dried overnight and stained by hematoxyline-eosin. GCs and mantle zones were isolated by laser capture microdissection using a Leica laser microdissection microscope. The microdissected regions were collected in RLT buffer (Qiagen). RNAs were extracted using the Qiagen RNeasy microkit following manufacturer's instructions. Reverse transcription and real-time PCR were performed on microdissected GCs as described above. The mantle zones were too small to provide enough material to perform RT-PCR.
Determination of total GC areas using the microarray scanner Affimetrix scanner using "Jaguar software". Total GC areas (CD21+) were determined by the number of Alexa-positive pixels out of the total number of pixels evaluated on the whole sections, using "Image J software".
Results
DNA Microarray experiment analysis
To identify genes mediating the effects of glucocorticoid treatments in MG, we first compiled a list of dysregulated genes in thymuses from untreated MG patients versus adult controls, and then analyzed the behavior of these genes in the thymus of glucocorticoid treated MG patients.
Statistical analysis
Using SAM analysis with a FDR<5% and a FC>1.8, we identified 157 genes up-regulated and 227 genes down-regulated in thymuses from untreated MG patients compared to adult controls. Using K-Medians clustering analysis on these 384 dysregulated genes, we found that glucocorticoid effects on the dysregulated genes during MG could be divided into four patterns ( Figure 1A ). Glucocorticoids totally normalized the expression of 23% (pattern I) of these genes, and partially normalized 30% (pattern II) of them. In contrast, they exerted no effect on the expression of 23% of the dysregulated genes (pattern III) and they accentuated the dysregulated expression of 23% of them (pattern IV). The lists of these genes are given in the Supplemental Data 1.
The beneficial effects of glucocorticoids may be due to their action on the genes of patterns I
and II (53 % of the dysregulated genes during MG). Their partial effects on some of the genes belonging to pattern II, and their lack of effects on genes of pattern III may explain some of their limits in MG treatment. Finally, the effect of glucocorticoids on the genes of pattern IV may explain their important side effects, especially during long-term treatment.
Altogether, these analyses indicate that about only half of the dysregulated genes during MG are normalized by corticotherapy. On the contrary, many genes are even more dysregulated with corticosteroids, evidencing the side effects of corticosteroids. However and since MG patients are improved after corticosteroid treatment, we hypothesize that the improvement is due to genes dyregulated during the pathology and normalized by the treatment.
Gene by gene analysis
To focus more precisely on the genes normalized by glucocorticoids, we carried out a "gene by gene analysis" on the genes belonging to patterns I and II (shown in Figure 1A ) using a Mann-Whitney test. Figure 1B indicates that among the 227 down-regulated genes during MG, 52 were normalized by glucocorticoids (the list of these genes is given in supplemental data 2) and among the 157 up-regulated genes during MG, 36 were normalized by glucocorticoids (Table 1) . Altogether, 88 (36+52) genes were dysregulated in MG thymus and normalized by corticotherapy. Fifteen out of the 36 genes (42%) were involved in the immune response and linked to B cell biology. It is noteworthy that CXCL13 is the gene on which glucocorticoids exert the most significant effect (Table 1 and Figure 2A ). Indeed CXCL13 expression was 2.82 fold higher in MG thymuses, and was completely normalized in
of glucocorticoid treated patients. We therefore decided to focus our research on the expression and function of CXCL13 in MG.
CXCL13 is overexpressed in MG thymuses and sera and normalized by corticotherapy
To confirm results obtained by DNA microarray (Figure 2A) , we analyzed CXCL13 RNA and protein expression levels in the thymus. We found that CXCL13 was overexpressed in MG thymuses when compared to adult and newborn controls and normally expressed in MG patients treated by corticotherapy (Figures 2B-C) . CXCL13 was also overexpressed in sera of untreated MG patients, while corticosteroid treated patients exhibited normal levels ( Figure   2D ). A significant correlation was found between thymic and serum CXCL13 expression of the same MG patients ( Figure 2E ). Thus CXCL13 expression was higher in MG patients untreated by corticosteroids in both the thymus and the serum and reduced to normal values in patients treated by corticotherapy.
The overexpression of CXCL13 in MG thymus contributes to high number of B cells in
MG thymic hyperplasia
We compared the chemoattractive effect of thymic extracts from MG patients and adult controls on normal B cells. As expected, we found that the thymic extracts from untreated MG patients exhibited the strongest chemoattractant effect on B cells ( Figure 3A) . The chemoattraction was strikingly reduced in thymic extracts from corticosteroid treated patients ( Figure 3A) . CXCL13 or CCL21 neutralization using specific antibodies resulted in a greater inhibition of B cell attraction in the first case than in the latter ( Figures 3B) . The use of anti-CXCR5 antibody also resulted in a partial inhibition of B cell migration (data not shown).
Thus, it is likely that the overexpression of CXCL13 in MG thymus contributes to high number of B cells in MG thymic hyperplasia.
GC numbers are reduced in MG patients treated with corticosteroids
CD21 is a GC marker because of its high expression by germinal B cells 27 . We analyzed the number of thymic GCs stained by anti-CD21 by means of an innovative use of the microarray scanner. As expected, the number of GCs was high in untreated MG patients. For the first time, we demonstrated that the number of GCs was dramatically reduced in corticosteroid treated MG patients ( Figure 3C ). Image analysis of the CD21+ areas indicates a high significant difference between thymuses from treated and untreated MG patients ( Figure 3D ).
These results demonstrate that glucocorticoids induce a striking reduction in the thymic GC formation.
All these results show that CXCL13 expression and function is increased in the thymus of untreated MG patients in correlation with a high number of GCs, while CXCL13 production is dramatically reduced in the thymus of MG patients treated with glucocorticoids and correlates with a low number of GCs.
The increase of CXCL13 in MG thymus is not only due to cells within GCs
CXCL13 is known to be produced by cells within GCs 18 ,28-30 . Therefore the increased CXCL13 expression in MG patients could be due to the high GC number. We analyzed the correlation between CXCL13 and CD21 or CXCR5, both normally expressed on B cells 27, 31 and thus in GCs. While expression of CD21 and CXCR5 was clearly correlated, no correlation could be found between CXCL13 and CD21 or CXCR5 mRNA levels in MG patient thymuses ( Figure 4A ). This suggests that the high levels of CXCL13 found in MG thymuses are not supplied only from the GCs.
To strengthen these results, CXCL13 mRNA expression was determined on thymic GC-free sections and the corresponding microdissected GC from untreated MG patient thymuses. We found that MG GC-free sections exhibited a higher CXCL13 mRNA level than total thymic sections from adult controls. Furthermore, the CXCL13 levels provided by microdissected
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GCs represented 1 to 12% of the total CXCL13 produced by the whole section ( Figure 4B ).
Thus, GC cells could not explain the higher production of CXCL13 observed in thymus from untreated MG patients. We next examined which cells are able to produce CXCL13 in the thymus.
CXCL13 is normally produced by TEC in the thymus
We tested the main thymic populations isolated from normal thymus for CXCL13 production: TEC, thymocytes, thymic fibroblasts and MITC (Myoid thymic cells). TEC were the only cells producing CXCL13 ( Figure 5A ). CXCL13 concentration in TEC culture supernatants increased from day 2 to 7 of subculture, suggesting an increase of CXCL13 production during the culture ( Figure 5A ). However, CXCL13 mRNA levels remained unchanged throughout the culture period ( Figure 5B ), suggesting that the increase of CXCL13 concentration in the culture supernatant is due to an accumulation of CXCL13 rather than to an increase of its production rate by TEC.
These results show that TEC are the primary source of CXCL13 in the thymus and suggest that the high levels of CXCL13 in MG may be due to a dysregulated expression in this cell type.
We then compared the CXCL13 mRNA level in TEC established from MG and control thymuses. The four TEC samples from MG patients overproduced CXCL13 ( Figure 5C ), suggesting a defect in the regulation of CXCL13 production by TEC during MG, leading to overexpression of this chemokine in the thymus.
Glucocorticoids inhibit CXCL13 production by TEC
We tested the effects of corticosteroids on CXCL13 production in-vitro by normal TEC after permeabilization. We found that dexamethasone inhibited CXCL13 expression in a dosedependent manner (Figures 6A-C) . It is noteworthy that under our culture conditions, the 
Thymectomy induces a decrease in CXCL13 concentration in patient sera
Since TEC is a major source of CXCL13 production, we should expect a decrease in CXCL13 concentration in the sera of MG patients after thymectomy. Indeed, the serum level of CXCL13 decreased in all the patients during the first months following thymectomy ( Figure   6D ). Interestingly, we found a correlation between the decrease of CXCL13 and a clinical improvement; most patients (groups 2 and 3) improved in the months following thymectomy and they showed a striking decrease in their CXCL13 serum concentration while patients not improved after thymectomy (group 1) exhibited the lowest reduction in CXCL13 serum concentration. Moreover, patients treated with corticoids at the time of thymectomy (group 3)
showed the most rapid decrease in CXCL13 concentration. These results confirm that the thymus is a significant source of CXCL13 in MG and that CXCL13 is both implicated in MG pathophysiology and serves as a glucocorticoid target.
Discussion
In the majority of chronic inflammatory diseases such as multiple sclerosis, asthma and psoriasis, multiple chemokines/receptors are present within lesions 32, 33 . In MG patients, the higher production of CXCL13 both in thymus and serum, the correlation between the thymic and peripheral CXCL13 levels, and the decrease after thymectomy strongly suggest that the thymus is a major producer of CXCL13. However, CXCL13
concentrations in patient serum remained sometimes higher than the level in controls, even many years after thymectomy (data not shown) suggesting the possible existence of another source of CXCL13 in the periphery. The question of the nature of the thymic cells producing CXCL13 could be raised. From previous reports, it is known that CXCL13 is produced by FDCs 18,28 and GC specific CD4 + CD57 + T cells 29, 30 . However, other data show that mature macrophages produce CXCL13, indicating that cellular types other than GC cells can be a 41 . In this study, we demonstrate that TEC are significant producers of this chemoattractant molecule.
The causes of the overproduction of CXCL13 by TEC from MG patients are not known.
Several hypotheses could be raised: 1) CXCL13 production could be induced due to the influence of the thymic environment. The triggering event(s) in MG disease is not known, but thymic hyperplasia is accompanied with signs of inflammatory activity 25 . However, since anxiety/depression/insomnia ("steroid psychosis"), glaucoma, osteoporosis, cataracts, opportunistic infections, muscle weakness, personality changes, and others 48 . Early attempts to circumvent these side-effects were largely unsuccessful, probably because of the large panel of genes on which glucocorticoids exert an effect. In this study, we found that glucocorticoids dysregulate 23% of genes whose expression is normal in MG thymuses.
These findings further highlight the lack of specificity of corticosteroid treatments and support the need to identify more specific therapeutic targets among the glucocorticoidregulated genes. Our results demonstrate for the first time that CXCL13 gene is a major target of glucocorticoids. Chemokines and their receptors might be good therapeutic targets in the treatment of inflammatory diseases. Strategies that have already been used to reduce chemokine/receptor activity include neutralizing antibodies, peptide antagonists, non peptide antagonists, and virally derived peptides [49] [50] [51] . The strategy of blocking the chemokine system to combat diseases is under investigation for the treatment of several diseases, and several chemokine receptors have been already targeted in the search for antagonists 51 . Therefore the targeting of CXCL13 in early steps of MG could inhibit B cell chemotaxis, and therefore limit thymic inflammation. This approach appears realistic, and is expected to be more specific and to have fewer side-effects than corticosteroids.
In conclusion, this study demonstrates the key role of CXCL13 gene in MG pathophysiology and its inhibition by glucocorticoids. Based on our data, CXCL13 could represent a future therapeutic target for this disease. 
